Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPARγ Agonists: A Potential Mechanism of Insulin Sensitization

• Published in: Endocrinology (Philadelphia) Vol. 143; no. 3; pp. 998 - 1007
• Main Authors: Combs, Terry P, Wagner, John A, Berger, Joel, Doebber, Tom, Wang, Wen-Jun, Zhang, Bei B, Tanen, Michael, Berg, Anders H, O’Rahilly, Stephen, Savage, David B, Chatterjee, Krishna, Weiss, Stuart, Larson, Patrick J, Gottesdiener, Keith M, Gertz, Barry J, Charron, Maureen J, Scherer, Philipp E, Moller, David E
• Format: Journal Article
• Language: English
• Published: Endocrine Society 01.03.2002
• ISSN: 0013-7227; 1945-7170
• DOI: 10.1210/endo.143.3.8662

Adipocyte complement-related protein of 30 kDa (Acrp30, adiponectin, or AdipoQ) is a fat-derived secreted protein that circulates in plasma. Adipose tissue expression of Acrp30 is lower in insulin-resistant states and it is implicated in the regulation of in vivo insulin sensitivity. Here we have characterized the ability of PPARγ agonists to modulate Acrp30 expression. After chronic treatment of obese-diabetic (db/db) mice with PPARγ agonists (11 d), mean plasma Acrp30 protein levels increased (>3×). Similar effects were noted in a nongenetic type 2 diabetes model (fat-fed and low-dose streptozotocin-treated mice). In contrast, treatment of mice (db/db or fat-fed) with metformin or a PPARα agonist did not affect plasma Acrp30 protein levels. In a cohort of normal human subjects, 14-d treatment with rosiglitazone also produced a 130% increase in circulating Acrp30 levels vs. placebo. In addition, circulating Acrp30 levels were suppressed 5-fold in patients with severe insulin resistance in association with dominant-negative PPARγ mutations. Thus, induction of adipose tissue Acrp30 expression and consequent increases in circulating Acrp30 levels represents a novel potential mechanism for PPARγ-mediated enhancement of whole-body insulin sensitivity. Furthermore, Acrp30 is likely to be a biomarker of in vivo PPARγ activation.